TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 30(12), 1350-1357.

Abstract

The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2(mut)) in AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact of TET2(mut) in a large cohort of patients with AML in the context of other AML-associated aberrations.

Leibniz-HKI-Authors

Marie von Lilienfeld-Toal

Identifier

doi: 10.1200/JCO.2011.39.2886

PMID: 22430270